Posts in category All News
Now, investors can help cancer patients via UTI Mutual (27-08-2015)
Upstream oil stocks: Time to take a contrarian call (27-08-2015)
Tata Motors: China worries persist (27-08-2015)
Alembic & Alembic Pharma (27-08-2015)
Hi Rudra,
Price erosion is always a very debatable topic and except for the pharma companies, I doubt anyone else knows about it accurately (it's an area where we should work on).
If you go through the article, it says 'Currently there is a limited competition for the product and the company can conservatively garner sales of US $50-60 million in sales for the 50 mg capsules' (would rather ignore what the journalists are writing and give more weightage to the analysts). The analyst is talking about 50 mg capsule while it is also availabe in 100 mg, 200 mg and 400 mg (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Generics&Mkt=1). I still dont know how to interpret it.
You will always find reports on negative reports on generics (may be propagated by the innovators themselves). Not exactly sure how serious they are about gCelebrex.
Ambika Cotton Mills (27-08-2015)
Ok.
All the best for your investing journey!
Nusli Wadia sells 19.26 lakh shares of Bombay Dyeing (27-08-2015)
Nusli Wadia offloaded more than 19.26 lakh shares of the textile company for over Rs 12 crore through an open market transaction.
Alembic & Alembic Pharma (27-08-2015)
Hello drrakesh,
the newer patent was a mere extension sought by Pfizer. Refer this article for the full context of this.
Judge Allen invalidated the reissue patent for the same reason the Federal Circuit invalidated the original one — “double-patenting.” Pfizer had argued that, as part of the reissue, it had reclassified the patent in a way that made it eligible for a safe harbor that protects patents from invalidation on “double-patenting” grounds. But Judge Allen found that the reissuance process could not be used for that purpose, and the flaw was therefore “not correctable.”
Alembic & Alembic Pharma (27-08-2015)
Thanks Ankit.
As per this news article, pegs the generic market for Celebrex at $400 million.
"Lupin currently holds 14 per cent market share for Celebrex and expect $58 million sales from the drug with a 15 per cent market share"
However, off late, there are reports of adverse effects from generic Celebrex, read here. So it is debatable how easy it will be for Alembic to garner market share.
Hindalco to raise ₹6,000 crore to fund capex (27-08-2015)
Ambika Cotton Mills (27-08-2015)
Hi Anil,
IMHO the link below can provide us insight that supply is not a concern yet as stock exists after taking into account local supply and exports.
http://www.supima.com/view-reports/supply-and-use/
The winds are favouring the Indian Textile industry and also factories in China are lowering their production due to high overhead costs and hence demand for raw material would decrease in China. The excess raw material can then make way to India.